Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2008

View Archived Issues

PDC and Theratechnologies sign license agreement for PDC-31

New treatments for cancer reported in recent patent literature

Oncolin announces results from preclinical animal testing of ONC-127 in cancer

GlaxoSmithKline reviews first quarter 2008 highlights

Terguride receives orphan drug designation for pulmonary arterial hypertension

Lpath initiate phase I clinical trial for iSONEP in patients with AMD

FDA puts Geron's IND application for GRNOPC1 on clinical hold

AVI BioPharma reports reproducible results from animal trials of AVI-6002 and AVI-6003

Sirtex initiates clinical trial of SIR-Spheres microspheres in HCC

Debiopharm enters license agreement for European marketing of Salvacyl/Moapar

MGH to conduct phase II trial of tesamorelin in growth hormone-deficient abdominal obesity

Novavax completes enrollment in phase I/IIa clinical trial of pandemic influenza vaccine

SynCo completes manufacture of ActoGeniX's AG-011 for phase II trial in ulcerative colitis

Medivir enters agreement with Tibotec for orally active HCV inhibitors

Pozen transfers IND and NDA for migraine drug Treximet to GSK

Progen resumes patient enrollment in phase I study of PG-11047 in advanced cancer

Poniard and Scripps Research Institute enter license agreement for protein kinase inhibitors

VIA Pharmaceuticals completes enrollment in phase II ACS trial of VIA-2291

Cerenis completes phase I clinical trial of CER-002 in cardiovascular disease

Protox initiates dosing in phase II clinical trial of PRX-302 in BPH

Southwest Foundation for Biomedical Research establishes new spin-off company

JNJ-17166864, a novel CCR2 antagonist with potential against inflammatory diseases

New antiinflammatory agents disclosed in recent Epix patents

Novel analgesic agents described in recent patents

Novel vaccine effective in murine model of autoimmune ovarian disease

Phase I results of MSP3-LSP malaria vaccine reported

Murine version of ACE-011 shows increased bone formation and strength in mouse model of osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...